BridgeMD
New treatment option for Solid Tumor
Official title A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
ClinicalTrials.gov ID: NCT06816108
What this study is testing
What is ONO-7428?
ONO-7428 is an investigational medicine, being studied as a potential treatment for solid tumor.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors. [Backfill cohort only] Participants with...
- Participants who are refractory or intolerant to standard therapy.
- Participants with a tumor type for which anti-PD-(L)1 antibodies have been approved and who have previously treated with anti-PD-(L)1 antibody...
- Participants with Eastern Cooperative Oncology Group Performance Status 0 or 1.
- Participants with tumor tissue samples available for biomarker testing.
You likely can't join if
- Participants with a complication or history of severe hypersensitivity to any other antibody drugs.
- Participants with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease
- Participants with severe peritoneal dissemination.
- Participants with pericardial fluid, pleural effusion, or ascites requiring treatment.
- Participants with uncontrolled tumor-related pain.
- Participants with active or history of interstitial lung disease or pulmonary fibrosis.
The study team makes the final eligibility decision.
Where it's taking place
- Nagoya, Aichi-ken, Japan
- Kashiwa, Chiba, Japan
- Kurume, Fukuoka, Japan
- Nishinomiya, Hyōgo, Japan
- Sagamihara, Kanagawa, Japan
- Yokohama, Kanagawa, Japan
- Nankoku, Kochi, Japan
- Kyoto, Kyoto, Japan
- Hirakata, Osaka, Japan
- Osaka, Osaka, Japan
- Sakai, Osaka, Japan
- Hidaka, Saitama, Japan
- Shinden, Saitama, Japan
- Bunkyō-Ku, Tokyo, Japan
- Koto-Ku, Tokyo, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nagoya, Aichi-ken, Japan; Kashiwa, Chiba, Japan; Kurume, Fukuoka, Japan; Nishinomiya, Hyōgo, Japan; Sagamihara, Kanagawa, Japan; Yokohama, Kanagawa, Japan and 9 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.